ArdorComm Media Group

Wednesday, October 7, 2026 7:14 PM

ICAR

ICAR Unveils India’s First Indigenous Vaccine Against African Swine Fever

The Indian Council of Agricultural Research (ICAR) has developed India’s first homegrown vaccine to combat African swine fever (ASF), marking a significant milestone in the country’s efforts to protect livestock from one of the world’s most destructive pig diseases. African swine fever, caused by the African swine fever virus (ASFV), is a highly contagious viral disease that affects both domestic and wild pigs and is known for causing extremely high mortality rates. ICAR described the vaccine’s development as a major advancement in strengthening India’s animal health ecosystem. ICAR Director General M.L. Jat hailed the achievement as a landmark in veterinary science, saying it demonstrates India’s growing capability to create globally competitive animal health technologies. He added that the breakthrough would enhance disease preparedness, improve livestock health, and contribute to the country’s food and biosecurity. The vaccine has been developed by scientists at the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), Bhopal, using a novel attenuated ASFV Genotype II strain. According to the Union Agriculture Ministry, the vaccine has successfully cleared a series of laboratory evaluations, including tests for sterility, purity, safety, genetic stability, immune response, protective efficacy, and the possibility of the virus regaining virulence. Designed for healthy pigs aged over eight weeks, the vaccine is administered as a 1 ml intramuscular injection, followed by a booster dose after 14 days. Officials believe the vaccine will play a crucial role in reducing pig mortality, limiting financial losses, and improving the livelihoods of pig farmers across the country. The Agriculture Ministry said the vaccine is expected to strengthen India’s animal health security by providing an effective preventive solution against ASF, while supporting the long-term sustainability of the pig farming industry. ASF has emerged as a major threat to the global livestock sector, with mortality rates that can reach nearly 100 per cent. Since the disease was first detected in India in 2020, it has spread across several states and Union Territories, leading to widespread pig deaths, disruptions in production, restrictions on livestock movement and trade, and severe economic hardship for farmers, particularly in the Northeastern region. In the absence of an approved vaccine or effective treatment until now, authorities have relied on rapid disease detection, culling infected animals, and enforcing strict biosecurity measures to contain outbreaks. The financial impact of ASF has been substantial. The Ministry noted that outbreaks in Assam during 2020 and 2021 resulted in estimated losses of around ₹276 crore due to pig deaths and culling. In Mizoram, the disease affected more than 11,382 households by 2025, with reported economic losses estimated at nearly ₹982 crore. Source: The Hindu  

ICAR Unveils India’s First Indigenous Vaccine Against African Swine Fever Read More »

India Approves Marker Vaccine for Lumpy Skin Disease in Cattle and Buffaloes

New Delhi, February 11: In a major breakthrough for animal health, India’s drug regulatory authority has approved a vaccine for cattle and buffaloes against lumpy skin disease (LSD), a viral infection that has severely impacted livestock farmers. The newly approved vaccine, Biolumpivaxin, developed by Biovet in collaboration with the Indian Council of Agricultural Research (ICAR), features a unique marker that differentiates infected animals from vaccinated ones. The Central Drugs Standard Control Organisation granted approval for the vaccine, which is expected to play a crucial role in curbing the spread of LSD and minimizing economic losses. The disease, which spreads through insect bites, has led to over 200,000 cattle deaths in India since 2022, causing a significant decline in milk production. “This DIVA marker vaccine could be a game-changer in veterinary medicine for disease surveillance, outbreak control, and eradication efforts,” said Krishna Ella, founder of Biovet. The Differentiating Infected from Vaccinated Animals (DIVA) technology allows rapid identification of unvaccinated animals, enabling targeted immunization efforts. With the risk of fresh LSD outbreaks expected in 2025, particularly post-monsoon, experts highlight the urgent need for widespread vaccination. Scientists warn that natural immunity from the 2022 outbreak has likely waned, making cattle populations vulnerable again. Biovet’s facility in Mallur, Karnataka, has the capacity to produce 500 million doses annually. While the vaccine is ready for commercial rollout, production timelines will depend on government procurement plans. The approval of Biolumpivaxin marks a significant step in disease control efforts, ensuring better livestock health and protecting the dairy industry from future outbreaks. Source: Telegraph

India Approves Marker Vaccine for Lumpy Skin Disease in Cattle and Buffaloes Read More »